Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, we are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.
Press Release_ Resistell_Jun2021
About HEMEX
HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany and Benelux, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients. For more information, visit https://hemex.ch/